Cargando…

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study

Background: We aimed to evaluate the factors associated with a virological response in a cohort of Hepatitis C virus (HCV)-infected people who inject drugs (PWID) treated with direct acting antivirals (DAAs). Methods: We conducted a multicenter retrospective cohort study enrolling HCV-infected PWID...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messina, Vincenzo, Onorato, Lorenzo, Di Caprio, Giovanni, Claar, Ernesto, Iovinella, Vincenzo, Russo, Antonio, Rosato, Valerio, Salzillo, Angela, Nevola, Riccardo, Simeone, Filomena, Curcio, Fabio, Pisaturo, Mariantonietta, Coppola, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824069/ https://www.ncbi.nlm.nih.gov/pubmed/33396802 http://dx.doi.org/10.3390/life11010017

Ejemplares similares

Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology?
por: Nevola, Riccardo, et al.
Publicado: (2022)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions
por: Rosato, Valerio, et al.
Publicado: (2022)

Rituximab-Based Treatment, HCV Replication, and Hepatic Flares
por: Sagnelli, Evangelista, et al.
Publicado: (2012)

Telemedicine Improves HCV Elimination among Italian People Who Use Drugs: An Innovative Therapeutic Model to Increase the Adherence to Treatment into Addiction Care Centers Evaluated before and during the COVID-19 Pandemic
por: Rosato, Valerio, et al.
Publicado: (2022)

Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review
por: Onorato, Lorenzo, et al.
Publicado: (2021)

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)
por: Pisaturo, Mariantonietta, et al.
Publicado: (2019)

Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease †
por: Alessio, Loredana, et al.
Publicado: (2022)

Can Telemedicine Optimize the HCV Care Cascade in People Who Use Drugs? Features of an Innovative Decentralization Model and Comparison with Other Micro-Elimination Strategies
por: Nevola, Riccardo, et al.
Publicado: (2022)

Unusual liver‐related heart injury
por: Nevola, Riccardo, et al.
Publicado: (2020)

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
por: Rinaldi, Luca, et al.
Publicado: (2019)

Peg-Interferon Plus Ribavirin with or without Boceprevir or Telaprevir for HCV Genotype 1: A Meta-Analysis on the Role of Response Predictors
por: Coppola, Nicola, et al.
Publicado: (2014)

Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients
por: Pietrosi, Giada, et al.
Publicado: (2020)

Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma
por: Pisaturo, Mariantonietta, et al.
Publicado: (2021)

Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression
por: Coppola, Nicola, et al.
Publicado: (2013)

Epidemiology and management of hepatitis C virus infections in immigrant populations
por: Coppola, Nicola, et al.
Publicado: (2019)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
por: Rinaldi, Luca, et al.
Publicado: (2020)

Dementia as Risk Factor for Severe Coronavirus Disease 2019: A Case-Control Study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2021)

Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases
por: Onorato, Lorenzo, et al.
Publicado: (2021)

Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2022)

Correction: Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
por: Pisaturo, Mariantonietta, et al.
Publicado: (2023)

Chronic hepatitis C, atherosclerosis and cardiovascular disease: What impact of direct-acting antiviral treatments?
por: Adinolfi, Luigi Elio, et al.
Publicado: (2018)

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort)
por: Buonomo, Antonio Riccardo, et al.
Publicado: (2020)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
por: Sagnelli, Caterina, et al.
Publicado: (2021)

Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features
por: Coppola, Nicola, et al.
Publicado: (2017)

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
por: Imperatore, Nicola, et al.
Publicado: (2017)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Low prevalence of HTLV1/2 infection in a population of immigrants living in southern Italy
por: Alessio, Loredana, et al.
Publicado: (2018)

A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort
por: Kondili, Loreta A., et al.
Publicado: (2022)

More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study
por: Monari, Caterina, et al.
Publicado: (2021)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Prognostic Value of Creatinine Levels at Admission on Disease Progression and Mortality in Patients with COVID-19—An Observational Retrospective Study
por: Russo, Antonio, et al.
Publicado: (2023)

Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon
por: Mascia, Claudia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2q94mikl8m2pet1rm79rqgsujj